Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Current Assets (2023 - 2025)

Beta Bionics' Current Assets history spans 3 years, with the latest figure at $267.9 million for Q4 2025.

  • For Q4 2025, Current Assets rose 101.55% year-over-year to $267.9 million; the TTM value through Dec 2025 reached $267.9 million, up 101.55%, while the annual FY2025 figure was $267.9 million, 101.55% up from the prior year.
  • Current Assets for Q4 2025 was $267.9 million at Beta Bionics, down from $270.0 million in the prior quarter.
  • Across five years, Current Assets topped out at $286.1 million in Q2 2025 and bottomed at $103.6 million in Q4 2023.
  • The 3-year median for Current Assets is $264.9 million (2025), against an average of $220.4 million.
  • The largest annual shift saw Current Assets rose 28.28% in 2024 before it skyrocketed 101.55% in 2025.
  • A 3-year view of Current Assets shows it stood at $103.6 million in 2023, then grew by 28.28% to $132.9 million in 2024, then surged by 101.55% to $267.9 million in 2025.
  • Per Business Quant, the three most recent readings for BBNX's Current Assets are $267.9 million (Q4 2025), $270.0 million (Q3 2025), and $286.1 million (Q2 2025).